These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 24471291)
1. [Croatian consensus on the treatment of inflammatory bowel diseases with biologic therapy]. Vucelić B; Cuković-Cavka S; Banić M; Bilić A; Borzan V; Duvnjak M; Katicić M; Kolacek S; Krznarić Z; Kujundzić M; Marusić M; Mihaljević S; Mijandrusić BS; Persić M; Simunić M; Skurla B; Stimac D; Tonkić A; Troskot B Acta Med Croatica; 2013 Apr; 67(2):75-87. PubMed ID: 24471291 [TBL] [Abstract][Full Text] [Related]
2. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Barrie A; Regueiro M Inflamm Bowel Dis; 2007 Nov; 13(11):1424-9. PubMed ID: 17567879 [TBL] [Abstract][Full Text] [Related]
3. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Moss AC; Brinks V; Carpenter JF Aliment Pharmacol Ther; 2013 Nov; 38(10):1188-97. PubMed ID: 24118102 [TBL] [Abstract][Full Text] [Related]
4. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease]. Kujundzić M Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303 [TBL] [Abstract][Full Text] [Related]
5. Stopping Biologics in IBD-What Is the Evidence? Louis E Inflamm Bowel Dis; 2018 Mar; 24(4):725-731. PubMed ID: 29548010 [TBL] [Abstract][Full Text] [Related]
6. The use of biologic therapy in pregnancy: a gastroenterologist's perspective. Hassid B; Mahadevan U Curr Opin Rheumatol; 2014 May; 26(3):347-53. PubMed ID: 24625373 [TBL] [Abstract][Full Text] [Related]
7. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Trivedi I; Hanauer SB Expert Opin Drug Saf; 2015; 14(12):1915-34. PubMed ID: 26559664 [TBL] [Abstract][Full Text] [Related]
9. Biologics for extraintestinal manifestations of IBD. Vavricka SR; Scharl M; Gubler M; Rogler G Curr Drug Targets; 2014; 15(11):1064-73. PubMed ID: 25198785 [TBL] [Abstract][Full Text] [Related]
10. Maximizing the effect of biologics in inflammatory bowel disease. Souto Rodriguez R; Swoger JM; Barreiro-De Acosta M; Regueiro M Minerva Gastroenterol Dietol; 2012 Jun; 58(2):101-22. PubMed ID: 22643594 [TBL] [Abstract][Full Text] [Related]
11. Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia. Connell W; Andrews JM; Brown S; Sparrow M Intern Med J; 2010 Feb; 40(2):139-49. PubMed ID: 20446955 [TBL] [Abstract][Full Text] [Related]
12. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Conrad MA; Kelsen JR Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562 [TBL] [Abstract][Full Text] [Related]
13. [Safety and effectiveness of biologics in treating inflammatory bowel diseases in pregnancy]. Tursi A Recenti Prog Med; 2010 Oct; 101(10):396-401. PubMed ID: 21137576 [TBL] [Abstract][Full Text] [Related]
14. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Chang S; Hudesman D Curr Gastroenterol Rep; 2020 Jan; 22(2):7. PubMed ID: 32002688 [TBL] [Abstract][Full Text] [Related]
16. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Armuzzi A; Gionchetti P; Daperno M; Danese S; Orlando A; Lia Scribano M; Vecchi M; Rizzello F; Dig Liver Dis; 2016 Apr; 48(4):360-70. PubMed ID: 26821929 [TBL] [Abstract][Full Text] [Related]
17. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. Zheng MK; Shih DQ; Chen GC World J Gastroenterol; 2017 Mar; 23(11):1932-1943. PubMed ID: 28373759 [TBL] [Abstract][Full Text] [Related]